BioCryst Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript
We're really happy to be hosting BioCryst today. With us today, we have Charlie Gayer, CEO; Babar Ghias, CFO; Nick Wilder, Head of IR.
So now that we're in the sixth year of launch, maybe just start with some opening remarks on the recent earnings performance.
Sure. Thanks, Stacy. And great to be here again.
Before I start, I will be making forward-looking statements. Those statements have risks. You can learn about them on our website.
For those who have looked at BioCryst before, you may have in the past, and we've been around for a while, this is a new BioCryst. Last year, we hit $601 million in revenue with ORLADEYO, $563 million after you exclude the fact that we sold our European business in October. We had $214 million in non-GAAP operating profits. So we're a profitable company and growing.
And we just completed the acquisition of Astria Therapeutics, which brings a late-stage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
